Annual EBITDA
-$15.74 M
-$1.16 M-7.94%
December 31, 2023
Summary
- As of February 7, 2025, ENTO annual EBITDA is -$15.74 million, with the most recent change of -$1.16 million (-7.94%) on December 31, 2023.
- During the last 3 years, ENTO annual EBITDA has risen by +$10.52 million (+40.06%).
- ENTO annual EBITDA is now -336.21% below its all-time high of -$3.61 million, reached on December 1, 2015.
Performance
ENTO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$1.89 M
+$1.50 M+44.22%
September 1, 2024
Summary
- As of February 7, 2025, ENTO quarterly EBITDA is -$1.89 million, with the most recent change of +$1.50 million (+44.22%) on September 1, 2024.
- Over the past year, ENTO quarterly EBITDA has increased by +$2.20 million (+53.74%).
- ENTO quarterly EBITDA is now -142.99% below its all-time high of $4.40 million, reached on September 1, 2022.
Performance
ENTO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$18.58 M
+$1.53 M+7.63%
September 1, 2024
Summary
- As of February 7, 2025, ENTO TTM EBITDA is -$18.58 million, with the most recent change of +$1.53 million (+7.63%) on September 1, 2024.
- Over the past year, ENTO TTM EBITDA has dropped by -$2.84 million (-18.03%).
- ENTO TTM EBITDA is now -2060.17% below its all-time high of -$860.30 thousand, reached on March 1, 2015.
Performance
ENTO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ENTO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.9% | +53.7% | -18.0% |
| 3 y3 years | +40.1% | +53.4% | -105.9% |
| 5 y5 years | -24.6% | +51.9% | -48.8% |
ENTO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7.9% | +72.8% | -143.0% | +82.9% | -138.1% | +69.0% |
| 5 y | 5-year | -14.7% | +72.8% | -143.0% | +93.8% | -138.1% | +71.1% |
| alltime | all time | -336.2% | +72.8% | -143.0% | +93.8% | -2060.2% | +71.1% |
Entero Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.89 M(-44.2%) | -$18.58 M(-7.6%) |
| Jun 2024 | - | -$3.39 M(-63.2%) | -$20.12 M(-3.8%) |
| Mar 2024 | - | -$9.21 M(+125.4%) | -$20.90 M(+32.8%) |
| Dec 2023 | -$15.74 M(+7.9%) | -$4.09 M(+19.3%) | -$15.74 M(+0.7%) |
| Sep 2023 | - | -$3.43 M(-18.0%) | -$15.63 M(+100.3%) |
| Jun 2023 | - | -$4.18 M(+3.0%) | -$7.80 M(-13.5%) |
| Mar 2023 | - | -$4.05 M(+2.1%) | -$9.02 M(-38.1%) |
| Dec 2022 | -$14.58 M(-74.8%) | - | - |
| Dec 2022 | - | -$3.97 M(-190.3%) | -$14.58 M(-32.6%) |
| Sep 2022 | - | $4.40 M(-181.5%) | -$21.64 M(-61.6%) |
| Jun 2022 | - | -$5.40 M(-43.9%) | -$56.31 M(-6.2%) |
| Mar 2022 | - | -$9.61 M(-12.9%) | -$60.05 M(+3.6%) |
| Dec 2021 | -$57.98 M(+120.8%) | -$11.03 M(-63.5%) | -$57.98 M(-9.7%) |
| Sep 2021 | - | -$30.26 M(+231.0%) | -$64.21 M(+69.3%) |
| Jun 2021 | - | -$9.14 M(+21.1%) | -$37.92 M(+22.2%) |
| Mar 2021 | - | -$7.55 M(-56.3%) | -$31.03 M(+18.1%) |
| Dec 2020 | -$26.27 M(+91.4%) | -$17.26 M(+334.6%) | -$26.27 M(+162.9%) |
| Sep 2020 | - | -$3.97 M(+76.3%) | -$9.99 M(+0.4%) |
| Jun 2020 | - | -$2.25 M(-19.2%) | -$9.96 M(-20.3%) |
| Mar 2020 | - | -$2.79 M(+183.8%) | -$12.49 M(-9.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$13.72 M(+8.6%) | -$982.10 K(-75.0%) | -$13.72 M(-17.2%) |
| Sep 2019 | - | -$3.93 M(-17.8%) | -$16.57 M(+10.4%) |
| Jun 2019 | - | -$4.78 M(+18.8%) | -$15.00 M(+13.0%) |
| Mar 2019 | - | -$4.03 M(+5.2%) | -$13.28 M(+5.1%) |
| Dec 2018 | -$12.63 M(+33.4%) | -$3.82 M(+61.4%) | -$12.63 M(+15.8%) |
| Sep 2018 | - | -$2.37 M(-22.6%) | -$10.91 M(-1.6%) |
| Jun 2018 | - | -$3.06 M(-9.4%) | -$11.09 M(+8.6%) |
| Mar 2018 | - | -$3.38 M(+60.5%) | -$10.21 M(+7.9%) |
| Dec 2017 | -$9.47 M(+19.5%) | -$2.10 M(-17.4%) | -$9.47 M(+8.8%) |
| Sep 2017 | - | -$2.55 M(+16.8%) | -$8.70 M(+3.1%) |
| Jun 2017 | - | -$2.18 M(-17.1%) | -$8.44 M(-10.7%) |
| Mar 2017 | - | -$2.63 M(+96.2%) | -$9.46 M(+19.4%) |
| Dec 2016 | -$7.92 M(+119.4%) | -$1.34 M(-41.4%) | -$7.92 M(+23.4%) |
| Sep 2016 | - | -$2.29 M(-28.4%) | -$6.42 M(+21.1%) |
| Jun 2016 | - | -$3.20 M(+191.9%) | -$5.30 M(+37.9%) |
| Mar 2016 | - | -$1.09 M(-776.2%) | -$3.84 M(+6.5%) |
| Dec 2015 | -$3.61 M | $161.90 K(-113.8%) | -$3.61 M(-4.3%) |
| Sep 2015 | - | -$1.17 M(-32.7%) | -$3.77 M(+45.0%) |
| Jun 2015 | - | -$1.74 M(+102.2%) | -$2.60 M(+202.2%) |
| Mar 2015 | - | -$860.30 K | -$860.30 K |
FAQ
- What is Entero Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Entero Therapeutics?
- What is Entero Therapeutics annual EBITDA year-on-year change?
- What is Entero Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Entero Therapeutics?
- What is Entero Therapeutics quarterly EBITDA year-on-year change?
- What is Entero Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Entero Therapeutics?
- What is Entero Therapeutics TTM EBITDA year-on-year change?
What is Entero Therapeutics annual EBITDA?
The current annual EBITDA of ENTO is -$15.74 M
What is the all time high annual EBITDA for Entero Therapeutics?
Entero Therapeutics all-time high annual EBITDA is -$3.61 M
What is Entero Therapeutics annual EBITDA year-on-year change?
Over the past year, ENTO annual EBITDA has changed by -$1.16 M (-7.94%)
What is Entero Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ENTO is -$1.89 M
What is the all time high quarterly EBITDA for Entero Therapeutics?
Entero Therapeutics all-time high quarterly EBITDA is $4.40 M
What is Entero Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ENTO quarterly EBITDA has changed by +$2.20 M (+53.74%)
What is Entero Therapeutics TTM EBITDA?
The current TTM EBITDA of ENTO is -$18.58 M
What is the all time high TTM EBITDA for Entero Therapeutics?
Entero Therapeutics all-time high TTM EBITDA is -$860.30 K
What is Entero Therapeutics TTM EBITDA year-on-year change?
Over the past year, ENTO TTM EBITDA has changed by -$2.84 M (-18.03%)